From discovery to product: the road that works

In the high stakes world of European biotechnology, a common pattern occurs every year. Billions of euros flow into basic research through university grants and European Innovation Council initiatives. These funds lead to breakthroughs that could change human health. Yet, most of these discoveries never leave the Valley of Death. This is the difficult gap between a successful lab experiment and a product that patients can actually use.

For a biotech venture builder, the cause of failure is rarely bad science. Instead, it is a failure of translation. Many academic spin outs start with a discovery looking for a problem, rather than a solution designed for a specific market. To cross this gap, you must treat translation as a strict discipline of design.

The mirage of the breakthrough

The academic world focuses on the breakthrough. In a lab, success means a published paper or a proven hypothesis. However, in venture building, a breakthrough is only the start.

The biggest mistake many founders make is assuming that great science automatically creates a great company. It does not. A discovery is a biological observation. A product is a regulated, scalable, and paid for medical intervention. The road that works starts by admitting that the "product" is actually the equity story. This is the logical map that proves to an investor that the science can become a valuable commercial asset.

The blueprint: the target product profile

If translation is like building a house, the target product profile (TPP) is the blueprint. In professional biotech, the TPP is a live document. It describes the final product: its medical use, the patients it helps, how it is given, and its advantage over other treatments.

For search engines and investors, the TPP shows that you are ready for business. It moves the talk from "how this works" to "how this wins." A strong TPP includes:

By creating the TPP on day one, a venture builder ensures that every euro spent in the lab helps create a future commercial reality.

The engine of de-risking: turning science into value

In the equity story framework, a biotech startup does not just do research. Its main job is to retire risk. Every experiment should be a risk retirement event. When you remove a risk, whether it is technical, regulatory, or industrial, you increase the value of the company. We call this the risk adjusted net present value (rNPV).

Technical de-risking

This means moving beyond interesting biology to solid proof. For a drug, this means showing it works in animal models that truly match human disease. For a diagnostic, it means moving from a lab prototype to a test that is accurate across thousands of samples.

Regulatory de-risking

The regulator, such as the EMA in Europe, is not a barrier. They are the final customer. The road that works involves talking to these groups early and often. A regulatory strategy is a design limit. If your trial does not meet what the regulator wants, your science has no commercial value.

Industrial risk: the CMC challenge

Perhaps the most ignored part of the journey is industrial risk, often called CMC (Chemistry, Manufacturing, and Controls). You must ask: "Is this drug producible at scale?"

A molecule that works in a small glass flask in a lab is not a product. To be a product, it must be stable, pure, and capable of being made in massive quantities without losing quality. If you cannot make the drug reliably or if the cost of making it is higher than what payers will pay, the asset is worthless. In the world of venture building, you solve CMC issues early. You do not want to reach clinical trials only to realize your manufacturing process cannot be scaled up.

Diagnostics versus therapeutics: two paths, one goal

The goal is always to help patients, but the path depends on what you are building.

The diagnostic path: proving clinical utility

In diagnostics and medtech, the biggest trap is a lack of clinical utility. It is not enough for a test to be accurate. In a crowded market, a test must change how a doctor acts. If the test result does not lead to a new treatment choice, it has no value. Venture builders must focus on health economics. You must prove that the test saves the system money or improves lives significantly.

The therapeutic path: beyond the biology

For drugs, you must align the mechanism of action with a clear recipe for production. Many founders focus only on the biology and forget the industrial side. Can the molecule be made at scale? Is it stable? Can it be delivered easily? A failure in making the drug is just as bad as a failure in the clinic. Large pharmaceutical companies will not buy an asset if the manufacturing process is a mess.

The math of the equity story

To understand why some biotechs raise €50 million while others struggle to raise €5 million, you must look at the math. Investors are not buying your science. They are buying a piece of the future value of a safe asset.

The rNPV is the ruler of this world. It is calculated by taking the potential sales, subtracting the costs, and multiplying by the chance of success.

A venture builder looks for the best ways to lower risk. If a €500,000 experiment can double the chance of success, it does not just double the value. It creates a massive jump in the equity story. This is the difference between a school project and a real company.

If a €500,000 experiment can double the chance of success, it does not just double the value. It creates a massive jump in the equity story.

Integration: the discipline of parallel development

The old way of building a biotech is a sequence: science, then regulatory, then manufacturing, then commercial. This is too slow and dangerous. The venture building model is parallel development.

While scientists work on the molecule, venture architects map out how the product will be paid for. While engineers build a prototype, production experts fix the CMC path, and storytellers refine the equity story. This integration keeps technology and business in sync.

The real buyer lens

The goal for most early stage biotech is to be bought by "Big Pharma" or a large MedTech company. Therefore, the road that works is seen through the eyes of the real buyer. What data does a Pharma business development team need to see to buy your company for millions of euros? They need to see that the science is sound, the regulators are happy, and the manufacturing is ready for the market.

Why the equity story is not a pitch

As I have noted before, your equity story is not a pitch. It is a thesis. A pitch is about excitement. A thesis is about logic and evidence.

When you show your biotech to an investor, you are not asking them to believe in the science. You are showing a logical path to create value. You are saying: "We found a big medical need, we have a plan to fix it, we have a way to make it at scale, and we have a step by step way to remove the risks."

The road forward for European biotech

Europe has amazing scientific talent but often lacks venture architecture. We have the people who can build with bricks, but we lack the architects who can design the skyscraper.

Moving from a discovery to a product is the hardest job in modern industry. It requires the precision of a scientist and the strategy of an investor. For those who treat translation as a discipline, the road is not a gamble. It is a clear path to turning a lab success into a life changing product.

My Venture Design Lab helps founders through this move, turning academic ideas into strong equity stories.

Frequently asked questions